23. Prion disease Clinical trials / Disease details
Clinical trials : 4 / Drugs : 5 - (DrugBank : 2) / Drug target gene : 0 - Drug target pathway : 0
No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
1 | EUCTR2010-022233-28-IT (EUCTR) | 20/06/2011 | 05/03/2012 | Fatal familial insomnia: preventive treatment with doxycycline of at risk individuals - Doxycycline in FFI individuals | Subjects born between 1958 and 1969 belonging to the Treviso FFI family, tested previously for Prion D178N/129M mutation MedDRA version: 14.1;Level: SOC;Classification code 10029205;Term: Nervous system disorders;System Organ Class: 10029205 - Nervous system disorders;Therapeutic area: Diseases [C] - Nervous System Diseases [C10] | Trade Name: BASSADO INN or Proposed INN: DOXYCYCLINE HYCLATE | IST. DI RICERCHE FARMACOLOG. M. NEGRI | NULL | Authorised-recruitment may be ongoing or finished | Female: yes Male: yes | Italy | |||||
2 | EUCTR2006-001858-27-IT (EUCTR) | 21/06/2006 | 12/04/2007 | A randomized, double-blind pilot study vs placebo for the evaluation of efficacy and tolerability of doxycline administered by oral route in patients affected by Creutzfeldt-Jakob disease. - ND | A randomized, double-blind pilot study vs placebo for the evaluation of efficacy and tolerability of doxycline administered by oral route in patients affected by Creutzfeldt-Jakob disease. - ND | Creutzfeldt-Jakob Disease. MedDRA version: 9.1;Level: LLT;Classification code 10011384;Term: Creutzfeldt-Jakob disease | Trade Name: BASSADO 10CPS 100MG INN or Proposed INN: Doxycycline | ISTITUTO NEUROLOGICO CARLO BESTA | NULL | Authorised-recruitment may be ongoing or finished | Female: yes Male: yes | Italy | ||||
3 | NCT00183092 (ClinicalTrials.gov) | April 2005 | 14/9/2005 | CJD (Creutzfeldt-Jakob Disease) Quinacrine Study | Novel Therapeutics For Prion Diseases: A Randomized, Double-blinded, Placebo-controlled Study of the Efficacy of Quinacrine in the Treatment of Sporadic Creutzfeldt-Jakob Disease | Creutzfeldt-Jakob Disease | Drug: Quinacrine;Drug: Placebo | University of California, San Francisco | National Institute on Aging (NIA) | Completed | 18 Years | N/A | All | 69 | Phase 2 | United States |
4 | NCT00104663 (ClinicalTrials.gov) | June 2004 | 3/3/2005 | PRION-1: Quinacrine for Human Prion Disease | PRION-1: Quinacrine for Human Prion Disease. A Partially Randomized Patient Preference Trial to Evaluate the Activity and Safety of Quinacrine in Human Prion Disease | Prion Disease | Drug: Quinacrine | Medical Research Council | NULL | Completed | 12 Years | N/A | Both | 160 | N/A | United Kingdom |